Effect of long-term and low-dose administration of erythromycin on proliferation of T lymphocytes stimulated with mitogens

Journal of Chemotherapy

Volumn 20, Issue 5, 2008, Pages 604-608

  Harita, Shingo ^a   Kuyama, S ^b   Okada, T ^b   Tanizaki, Y ^b  

^a CHUGOKU CENTRAL HOSPITAL   (Japan)

^b NONE

Author keywords

CD4+ cells; CD8+ cells; Con A; Erythromycin; PHA

Indexed keywords

CONCANAVALIN A; ERYTHROMYCIN; MITOGENIC AGENT; PHYTOHEMAGGLUTININ;

ADULT; AGED; ARTICLE; BRONCHIECTASIS; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LONG TERM CARE; LONG TERM EXPOSURE; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION; MALE; RESPIRATORY TRACT INFLAMMATION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION;

EID: 57049132905     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.5.604     Document Type: Article

References (18)

1. Kudoh S, Uetake T, Hagiwara K et al. Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 1987; 25: 632-42 (in Japanese).
2. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomized, placebo-controlted crossover trial. Lancet 2002; 360: 978-84.
3. Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin suppresses interleukin 6 expression by human bronchial epitherial cells; a potential mechanism of its anti-inflammatory action. Biochem Biophys Res Commun. 1995; 210: 781-6.
4. Iino Y, Toriyama M, Kudo K, Natori Y, You A. Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro. Ann Otol Rhinol Laryngol Suppl. 1992; 157: 16-20.
5. Oishi K, Sonoda F, Kobayashi S et al. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun 1994; 62: 4145-52.
6. Kadota J, Sakito O, Kohno S et al. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993; 147: 153-9.
7. Keicho N, Kudoh S, Yotsumoto H et al. Erythromycin promotes monocyte to macrophage differentiation. J Antibiot (Tokyo) 1994; 47: 80-9.
8. Keicho N, Kudoh S, Yotsumoto H et al. Anti-lymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A. J Antibiot (Tokyo) 1993; 46: 1406-13.
9. Forsgren A, Banck G, Beckman H, Bellahsene A. Antibiotic-host defence interactions in vitro and in vivo. Scand J Infect Dis 1980; Suppl 24: 195-203.
10. Konno S, Adachi M, Asano K et al. Inhibition of human T-lymphocyte activation by macrolide antibiotic, roxithromycin. Life Sci 1992; 51: 231-6.
11. Reinherz EL, Kung PC, Goldstein G, Schlossman SF. Separation of functional subsets of human T cells by a monoclonal antibody. Proc Natl Acad Sci USA 76: 4061-5, 1979.
12. Silva JR, Jones JA, Cole PJ, Poulter LW. The immunological compotent of the cellular inflammatory infiltrate in bronchiectasis. Thorax 1989; 44: 668-73.
13. Mukae H, Kadota J, Kohno S et al. Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis. Am J Respir Crit Care Med 1995; 152: 613-8.
14. Kawakami K, Kadota J, Iida K et al. Phenotypic characterization of T cells in bronchoalveolar lavage fluid (BALF) and peripheral blood of patients with diffuse panbronchiolitis; the importance of cytotoxic T cells. Clin Exp Immunol 1997; 107: 410-6.
15. Azuma A, Kudoh S. Diffuse panbronchiolitis in East Asia. Respirology, 2006; 11: 249-61.
16. Haring JS, Badovinac VP, Harty JT. Inflaming the CD8+ T cell response. Immunity, 2006; 25: 19-29.
17. Tetley TD. Inflammatory cells and chronic obstructive pulmonary disease. Curr Drug Targets-Inflamm Allergy, 2005; 4:607-18.
18. Hodge S, Hodge G, Nairn J, Holmes M, Reynolds PN. Increased airway granzyme b and perforin in current and ex-smoking COPD subjects. COPD, 2006; 3: 179-87.